Alpha-lipoic acid vs Benfotiamine
The two supplements with real randomized programs in diabetic peripheral neuropathy, different mechanisms, and the same ceiling: symptom scores move, the nerve does not.
Short answer
Neither alpha-lipoic acid nor benfotiamine needs a prescription, and both have human data, so the goal decides it. Alpha-lipoic acid is marketed for nerve pain, blood sugar, weight loss and antioxidant support; benfotiamine is the choice for readers interested in diabetic neuropathy, nerve health, anti-glycation and AGE defense.
Alpha-lipoic acid
Thioctic acid; NOT alpha-linolenic acid
Genuinely reduces diabetic neuropathy symptoms (licensed for it in Germany), but the 4-year NATHAN 1 trial missed its primary endpoint, weight loss is under a kilogram, and it can trigger autoimmune hypoglycemia in HLA-DRB1*04:06 carriers.
Full Alpha-lipoic acid evidence reviewBenfotiamine
S-benzoylthiamine O-monophosphate, milgamma
Raises thiamine far better than thiamine HCl and activates the transketolase shunt exactly as advertised — but the 12-month BOND trial found no effect on nerve structure or function.
Full Benfotiamine evidence reviewAlpha-lipoic acid vs Benfotiamine: head to head
- FDA status / approved use
Alpha-lipoic acid
Approved drug for diabetic neuropathy in Germany; sold as an unapproved dietary supplement in the USBenfotiamine
Unapproved dietary supplement in the US; licensed pharmacy medicine in Germany- Marketed for
Alpha-lipoic acid
Nerve pain, blood sugar, weight loss, antioxidantBenfotiamine
Diabetic neuropathy, nerve health, anti-glycation / AGE defense- Outcome areas
Alpha-lipoic acid
Blood sugar / insulin sensitivity; Weight loss / appetiteBenfotiamine
Blood sugar / insulin sensitivity- Evidence grade
Alpha-lipoic acid
Clinical dataBenfotiamine
Clinical data- How it works
Alpha-lipoic acid
Redox-active acid that acts on thiol and antioxidant systems and cell signalingBenfotiamine
Raises thiamine diphosphate, activating transketolase to divert glucose metabolites from damage pathways- Route and dosing
Alpha-lipoic acid
Oral capsule, typically 600 mg daily; given intravenously in GermanyBenfotiamine
Oral supplement or tablet; trials commonly used 300 mg twice daily- Headline human result
Alpha-lipoic acid
Oral 600 mg/day cut neuropathy symptom score 4.9 points (51%) vs 2.9 points (32%) on placebo in the SYDNEY 2 trialBenfotiamine
No effect on corneal nerve fiber length vs placebo in the 12-month BOND trial (2026) of 57 people with diabetic neuropathy- Strongest evidence
Alpha-lipoic acid
Ziegler 2004 meta-analysis, Diabet MedAlpha-lipoic acid evidence reviewPubMed 14984445Benfotiamine
BOND trial, BMJ Open Diab Res Care 2026Benfotiamine evidence reviewPubMed 41571333- Key safety signal
Alpha-lipoic acid
Can trigger insulin autoimmune syndrome with severe low blood sugar, mainly in HLA-DRB1*04:06 carriersBenfotiamine
Adverse events similar to placebo; increased ALT most often reported; metformin may reduce thiamine uptake- How it is obtained
Alpha-lipoic acid
Over the counter as a dietary supplementBenfotiamine
Over the counter as a dietary supplement
| Alpha-lipoic acid | Benfotiamine | |
|---|---|---|
| FDA status / approved use | Approved drug for diabetic neuropathy in Germany; sold as an unapproved dietary supplement in the US | Unapproved dietary supplement in the US; licensed pharmacy medicine in Germany |
| Marketed for | Nerve pain, blood sugar, weight loss, antioxidant | Diabetic neuropathy, nerve health, anti-glycation / AGE defense |
| Outcome areas | Blood sugar / insulin sensitivity; Weight loss / appetite | Blood sugar / insulin sensitivity |
| Evidence grade | Clinical data | Clinical data |
| How it works | Redox-active acid that acts on thiol and antioxidant systems and cell signaling | Raises thiamine diphosphate, activating transketolase to divert glucose metabolites from damage pathways |
| Route and dosing | Oral capsule, typically 600 mg daily; given intravenously in Germany | Oral supplement or tablet; trials commonly used 300 mg twice daily |
| Headline human result | Oral 600 mg/day cut neuropathy symptom score 4.9 points (51%) vs 2.9 points (32%) on placebo in the SYDNEY 2 trial | No effect on corneal nerve fiber length vs placebo in the 12-month BOND trial (2026) of 57 people with diabetic neuropathy |
| Strongest evidence | Ziegler 2004 meta-analysis, Diabet MedAlpha-lipoic acid evidence reviewPubMed 14984445 | BOND trial, BMJ Open Diab Res Care 2026Benfotiamine evidence reviewPubMed 41571333 |
| Key safety signal | Can trigger insulin autoimmune syndrome with severe low blood sugar, mainly in HLA-DRB1*04:06 carriers | Adverse events similar to placebo; increased ALT most often reported; metformin may reduce thiamine uptake |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Alpha-lipoic acid has the deeper file, and it is still bounded. A meta-analysis of four placebo-controlled trials in 1,258 patients found 600 mg intravenously daily for three weeks improved the Total Symptom Score by 24.1% over placebo, and SYDNEY 2 showed oral 600 mg daily improved symptoms with higher doses buying nothing extra — but a 2023 meta-analysis of ten oral trials found no improvement in the visual analog pain scale, vibration perception threshold or nerve conduction, and the four-year NATHAN 1 trial in 460 patients missed its primary composite endpoint (P = 0.105) with more serious adverse events on drug than on placebo. Benfotiamine's pharmacology is the best-proven part of it, delivering roughly elevenfold the plasma thiamine exposure of thiamine hydrochloride, and the 12-month BOND trial confirmed that end of the chain by raising all six thiamine analytes it measured — yet corneal nerve fiber length did not differ from placebo, and neither did any morphometric, neurophysiological, clinical or quality-of-life outcome, with only the Neuropathy Symptom Score even trending (p = 0.098). Both are licensed medicines in Germany and unapproved supplements in the United States, they have never been compared with each other, and two different mechanisms have now hit the same wall.
Alpha-lipoic acid fits if
Alpha-lipoic acid is the better-supported of the two for symptomatic diabetic polyneuropathy at 600 mg a day, provided the insulin-autoimmune-syndrome signal in HLA-DRB1*04:06 carriers is treated as a real contraindication rather than a footnote.
Benfotiamine fits if
Benfotiamine makes sense mainly for correcting a documented thiamine-pathway deficit in someone with diabetes, since raising thiamine is the one thing it has unambiguously been shown to do.
Alpha-lipoic acid vs Benfotiamine: common questions
- Is either alpha-lipoic acid or benfotiamine FDA-approved?
- No. Alpha-lipoic acid is an approved drug for diabetic neuropathy in Germany; sold as an unapproved dietary supplement in the US. Benfotiamine is an unapproved dietary supplement in the US; licensed pharmacy medicine in Germany.
- Which has stronger human evidence, alpha-lipoic acid or benfotiamine?
- Neither clearly. Both have human clinical data. The key source for alpha-lipoic acid is Ziegler 2004 meta-analysis, Diabet Med; for benfotiamine, it is BOND trial, BMJ Open Diab Res Care 2026.
- What are the main safety concerns with alpha-lipoic acid and benfotiamine?
- Alpha-lipoic acid can trigger insulin autoimmune syndrome with severe low blood sugar, mainly in HLA-DRB1*04:06 carriers. With benfotiamine, adverse events were similar to placebo; increased ALT most often reported; metformin may reduce thiamine uptake.
Key studies behind each
Alpha-lipoic acid
- Cronan JE. (2016). Assembly of Lipoic Acid on Its Cognate Enzymes: an Extraordinary and Essential Biosynthetic Pathway. Microbiol Mol Biol Rev. PubMed 27074917
- Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. PubMed 19664690
- Keith DJ, Butler JA, Bemer B, et al. (2012). Age and gender dependent bioavailability of R- and R,S-α-lipoic acid: a pilot study. Pharmacol Res. PubMed 22609537
- Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. (2004). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. PubMed 14984445
Benfotiamine
- Volvert ML, Seyen S, Piette M, et al. (2008). Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. PubMed 18549472
- Hammes HP, Du X, Edelstein D, et al. (2003). Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. PubMed 12592403
- Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. (2003). Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. PubMed 12882930
- Xie F, Cheng Z, Li S, Liu X, Guo X, Yu P. (2014). Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. J Clin Pharmacol. PubMed 24399744
The full evidence reviews
- Alpha-Lipoic Acid: Evidence, Dosing and Safety
Alpha-lipoic acid is a licensed neuropathy drug in Germany and an unapproved supplement in the US — with strong diabetic-neuropathy data, a marginal ~0.7 kg weight effect, and a real, ancestry-linked risk of autoimmune hypoglycemia.
Updated August 2026
- Benfotiamine: what the evidence actually shows
Benfotiamine delivers roughly 11× the thiamine of ordinary vitamin B1 and feeds a genuinely elegant mechanism — but the 12-month BOND trial found no effect on nerve structure or function, and the nephropathy trials were negative too.
Updated August 2026